Professor Clive Prestidge, the lead researcher, emphasizes that the formulation enhances the dispersion and absorption of limonene in the body, thereby improving its therapeutic benefits.

The new formulation has demonstrated 180-fold better solubility and over 4,000% increased bioavailability compared to pure limonene in lab and pre-clinical trials.

The formulation combines limonene with healthy lipids to enhance absorption and effectively target salivary glands, improving saliva production.

Described as a 'super-solubilising' treatment, this new limonene-lipid combination minimizes side effects while maximizing therapeutic effectiveness.

Researchers from the University of South Australia and Stanford University have developed a new citrus oil formulation that combines limonene with a lipid delivery system, effectively relieving dry mouth in cancer patients undergoing radiotherapy.

Dry mouth, or xerostomia, affects up to 70% of head and neck cancer patients post-radiotherapy, leading to significant difficulties in speaking and swallowing, which can severely reduce their quality of life.

Limonene is recognized for its protective effects on saliva production; however, its poor solubility has traditionally necessitated high doses that can lead to digestive discomfort.

This limonene-lipid combination allows for lower dosing while increasing saliva production and reducing dry mouth symptoms without the adverse effects associated with high doses of pure limonene.

The new formulation allows for effective lower doses of limonene without significant side effects such as stomach pain or 'citrus burps,' making it a more tolerable option for patients.

Dr. Leah Wright highlights the formulation's potential to significantly enhance the quality of life for cancer patients suffering from dry mouth.

Current clinical trials for the limonene-lipid formula are ongoing, with updates on next steps expected to be announced soon.